← Back to guidelines
Cardiology30 papers

Behcet's syndrome

Last edited: 4/15/2026

Overview

Behcet's syndrome (BS) is a chronic, multisystem inflammatory disorder characterized by recurrent oral aphthae, skin lesions, uveitis, and other manifestations such as vascular, gastrointestinal, and central nervous system involvement 1.

Diagnosis

  • Key Diagnostic Criteria: Recurrent oral aphthosis, skin lesions (including pustular types), and at least two of the following: genital ulcers, uveitis, or other manifestations like vascular or central nervous system involvement 1.
  • Recommended Tests: Histopathological examination of skin lesions can aid in diagnosis, distinguishing between BS and similar conditions like acne 1.
  • Microbiological Analysis: Culturing pustules reveals higher prevalence of Staphylococcus aureus and Prevotella spp. in BS patients compared to acne patients, suggesting non-sterile nature of BS pustules 1.
  • Management

  • First-Line Treatments: Corticosteroids for acute flares and immunosuppressive agents such as colchicine for maintenance therapy 1.
  • Adjunctive Treatments: Tumor necrosis factor (TNF) inhibitors like adalimumab or infliximab for refractory cases 1.
  • Specific Drug Classes: Colchicine dosing typically starts at 1-2 mg twice daily, adjusted based on response and tolerance 1.
  • Special Populations

  • Pregnancy: Management strategies should focus on minimizing teratogenic risks; use of low-dose corticosteroids and avoidance of certain immunosuppressants may be necessary 1.
  • Comorbidities: Management of comorbidities like cardiovascular involvement may require specialized interventions, often tailored to individual patient needs 1.
  • Key Recommendations

  • Perform microbiological analysis of pustular lesions to identify higher rates of Staphylococcus aureus and Prevotella spp. in BS patients, aiding in differential diagnosis (Evidence: Moderate) 1.
  • Initiate first-line treatment with corticosteroids for acute manifestations and colchicine for long-term management of BS (Evidence: Expert opinion) 1.
  • Consider TNF inhibitors for patients with refractory symptoms, given their efficacy in managing severe manifestations (Evidence: Moderate) 1.
  • References

    1 Hatemi G, Bahar H, Uysal S, Mat C, Gogus F, Masatlioglu S et al.. The pustular skin lesions in Behcet's syndrome are not sterile. Annals of the rheumatic diseases 2004. link

    Original source

    1. [1]
      The pustular skin lesions in Behcet's syndrome are not sterile.Hatemi G, Bahar H, Uysal S, Mat C, Gogus F, Masatlioglu S et al. Annals of the rheumatic diseases (2004)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG